IL5RA and asthma: ,25, 26, 27, 28, 29, 30 Benralizumab has been shown to reduce other cell types expressing IL-5Rα, including basophils (which contribute to an asthma endotype characterised by peripheral blood basophilia), IL-5Rα-positive type 2 innate lymphoid cells, and eosinophil lineage-committed progenitor cells.23